NT5C3A and neoplasm: Dynamic imaging (Fig. 3A−C) together with biodistribution (Fig. 3D) following administration of [18F]rucaparib (2.38–11.38 MBq, 30.9 GBq/μmol) to PSN1 tumour-bearing mice (n=3) showed that [18F]rucaparib is eliminated via multiple pathways, such as hepatobiliary and renal, resulting in uptake in liver, small and larger intestines, kidneys and bladder.